热门资讯> 正文
NanoVibronix向股东发出信函
2025-11-19 22:43
- NanoVibronix (NASDAQ:NAOV) announced on Wednesday the issuance of a letter to shareholders, highlighting the company’s strategic vision, market opportunities, and a rebranding initiative.
- To reflect our new strategic direction, the company is planning to rebrand its name from NanoVibronix to ENvue Medical, accompanied by a new NASDAQ ticker symbol.
- The ENvue feeding-tube placement system, which was merged with the company in early 2025, was the strongest and most scalable growth platform.
- ENvue’s potential will be useful in pediatrics and preterm infants, X-ray navigation overlay, vascular access, and robotic tube placement. Together, these opportunities demonstrate that ENvue is more than a single product. It is a broad navigation technology platform with the potential to transform multiple critical-care procedures.
- In the coming weeks, the company will introduce our Board of Directors following our Annual Meeting on December 4, 2025, announce key additions to our leadership team, and share early clinical progress that further validates the impact of ENvue.
More on NanoVibronix
- Seeking Alpha’s Quant Rating on NanoVibronix
- Financial information for NanoVibronix
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
